Wird geladen...
Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
New treatment options constitute unmet needs for patients diagnosed with systemic lupus erythematosus (SLE). Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal m...
Gespeichert in:
| Veröffentlicht in: | Front Pharmacol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6372521/ https://ncbi.nlm.nih.gov/pubmed/30787878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00082 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|